Tyrosine Kinase Inhibitors Are Promising Therapeutic Tools for Cats with HER2-Positive Mammary Carcinoma

Tyrosine Kinase Inhibitors Are Promising Therapeutic Tools for Cats with HER2-Positive Mammary Carcinoma

Feline mammary carcinoma (FMC) is a common neoplasia in cat, being HER2-positive the most prevalent subtype. In woman’s breast cancer, tyrosine kinase inhibitors (TKi) are used as a therapeutic option, by blocking the phosphorylation of the HER2 tyrosine kinase domain. Moreover, clinical trials demo...

Full description

Bibliographic Details
Main Authors: Andreia Gameiro, Filipe Almeida, Catarina Nascimento, Jorge Correia, Fernando Ferreira
Format: Article
Language:English
Published: MDPI AG 2021-03-01
Series:Pharmaceutics
Subjects:
feline mammary carcinoma
HER2
tyrosine kinase inhibitors
targeted therapies
feline her2 TK mutations
Online Access:https://www.mdpi.com/1999-4923/13/3/346

Similar Items

Similar Items